China Cancer Immunotherapy Market Size & Outlook
China cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
China cancer immunotherapy market highlights
- The China cancer immunotherapy market generated a revenue of USD 4,613.6 million in 2023 and is expected to reach USD 10,959.8 million by 2030.
- The China market is expected to grow at a CAGR of 13.2% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer immunotherapy market data book summary
| Market revenue in 2023 | USD 4,613.6 million |
| Market revenue in 2030 | USD 10,959.8 million |
| Growth rate | 13.2% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, China accounted for 3.7% of the global cancer immunotherapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 9,004.2 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 68.29% in 2023. Horizon Databook has segmented the China cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
China contributes significantly to the global cancer burden, accounting for nearly 4 million cancer cases each year. Malignancies of the lung, stomach, and liver are the most common cancer types. Lack of modern diagnostic tools and low consumer awareness are some of the main factors responsible for late diagnosis of most cancer cases in the country, thus limiting treatment options and lowering the survival rate.
Opdivo's approval for NSCLC treatment and Keytruda for melanoma treatment in 2018 marked the entry of immunotherapy in the country. China presents large commercial opportunities in cancer immunotherapy market. The country is gradually being heralded for its potential in biomedical science. Furthermore, availability of effective immunotherapy at cost-effective rates is likely to drive wide-scale accessibility and market penetration.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China cancer immunotherapy market size, by product, 2018-2030 (US$M)
China Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
